Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - recombinant human deoxyribonuclease - תמיסה לשאיפה - recombinant human deoxyribonuclease 1 mg/ml - dornase alfa (desoxyribonuclease) - dornase alfa (desoxyribonuclease) - management of cystic fibrosis not for patients under 5 years of age or with fvc<40% .

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab emtansine - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab emtansine 20 mg/ml - trastuzumab

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - cobimetinib as hemifumarate - טבליות מצופות פילם - cobimetinib as hemifumarate 20 mg

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - mosunetuzumab - תרכיז להכנת תמיסה לאינפוזיה - mosunetuzumab 1 mg / 1 ml

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - טבליות מצופות פילם - pirfenidone 267 mg - pirfenidone

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - טבליות מצופות פילם - pirfenidone 801 mg - pirfenidone